Scilex Holding (SCLX) Share-based Compensation (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Share-based Compensation of $16.2 million for Q1 2026, up 388.84% year-over-year from $3.3 million in Q1 2025, and up 317.48% quarter-over-quarter from -$7.4 million in Q4 2025.
Scilex Holding (SCLX) Share-based Compensation (2022 - 2026) Analysis & Trends
Scilex Holding's Share-based Compensation history runs 5 years deep, the most recent figure standing at $16.2 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 388.84% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $16.2 million (up 4.89% YoY), while the FY2025 annual figure was $20.0 million, down 28.06% from the prior year.
- Share-based Compensation for Q1 2026 stood at $16.2 million, up from -$7.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $17.2 million in Q3 2025, with the low at -$8.9 million in Q4 2023.
- The 5-year median for Share-based Compensation is $3.6 million (2024), against an average of $3.5 million.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation sank 269.39% in 2023, then soared 388.84% in 2026.
- Scilex Holding's Share-based Compensation stood at $5.3 million in 2022, then tumbled by 269.39% to -$8.9 million in 2023, then soared by 153.72% to $4.8 million in 2024, then plunged by 255.03% to -$7.4 million in 2025, then jumped by 317.48% to $16.2 million in 2026.
- Business Quant data shows SCLX's Share-based Compensation at $16.2 million in Q1 2026, -$7.4 million in Q4 2025, and $17.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 12.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.20 Mn |
| Mar 31, 2026 | 16.20 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Sep 30, 2025 | 17.20 Mn |
| Sep 30, 2025 | 17.20 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2023 | -8.94 Mn |
| Dec 31, 2023 | -8.94 Mn |